Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Index Rebalance

Suzhou Dongshan Precision A / Index Rebalance

<ul>
<li>Nearing the announcement of the changes in June, we forecast 5 potential constituent changes for the <a href="https://www.smartkarma.com/entities/ishares-ftse-a50-china-index-etf" target="_blank" data-smartkarma-citation="entities:249:1" rel="noopener">iShares A50 China (2823 HK)</a> / <a href="https://www.smartkarma.com/entities/csop-ftse-china-a50-etf-26e3b671-fa47-4165-a12e-bf841640c5a3" target="_blank" data-smartkarma-citation="entities:23664:1" rel="noopener">CSOP China A50 (HKD) (2822 HK)</a>. </li>
<li>Passive trackers are estimated to trade between 0.05 to 0.65 days of ADV in the forecast changes.</li>
<li>The forecast adds have outperformed the forecast deletes over the last 2 months and the recent pullback offers an entry point into the implementation trade.</li>
</ul>


Nearing the announcement of the changes in June, we forecast 5 potential constituent changes for the iShares A50 China (2823 HK) / CSOP China A50 (HKD) (2822 HK). 
Passive trackers are estimated to trade between 0.05 to 0.65 days of ADV in the forecast changes.
The forecast adds have outperformed the forecast deletes over the last 2 months and the recent pullback offers an entry point into the implementation trade.


China A50 ETFs Rebalance Preview: 5 Changes in June as the AI-Driven Churn Continues

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyze the 4Q2025 Shanghai/Shenzhen northbound Connect flows with our data engine as the exchange changed the rule to only disclose north bound position once a quarter.</li>
<li>We estimate that the inflows in 4Q2025 were US$1,590 million and holdings were US$368 billion.</li>
<li>We highlight flows for CATL, CATL, Moutai, Moutai, Luxshare Precision, Luxshare Precision, WEICHAI POWER, WEICHAI POWER, WUXI APPTEC, WUXI APPTEC, BYD, CMB, Mindray, EAST MONEY INFORMATION.</li>
</ul>


We analyze the 4Q2025 Shanghai/Shenzhen northbound Connect flows with our data engine as the exchange changed the rule to only disclose north bound position once a quarter.
We estimate that the inflows in 4Q2025 were US$1,590 million and holdings were US$368 billion.
We highlight flows for CATL, CATL, Moutai, Moutai, Luxshare Precision, Luxshare Precision, WEICHAI POWER, WEICHAI POWER, WUXI APPTEC, WUXI APPTEC, BYD, CMB, Mindray, EAST MONEY INFORMATION.


Northbound Flows (4Q2025): CATL, CATL, Moutai, Moutai, Luxshare Precision, Luxshare Precision

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>In this note, we will take a look at the Asia Pacific IPO pipeline for 2026, starting with Hong Kong.</li>
<li>This list has been compiled on a best effort basis from tracking the company filings and through various other sources.</li>
<li>The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.</li>
</ul>


In this note, we will take a look at the Asia Pacific IPO pipeline for 2026, starting with Hong Kong.
This list has been compiled on a best effort basis from tracking the company filings and through various other sources.
The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.


Aequitas 2026 Asia IPO Pipeline - Hong Kong

<ul>
<li>We analysed the earning revision of component stocks of CSI 100 in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on PING AN INSURANCE, CITIC SECURITIES, SHANDONG GOLD MINING, POLY DEVELOPMENTS AND, EAST MONEY INFORMATION, Longi Green, ZHONGJI INNOLIGHT, SERES.</li>
</ul>


We analysed the earning revision of component stocks of CSI 100 in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on PING AN INSURANCE, CITIC SECURITIES, SHANDONG GOLD MINING, POLY DEVELOPMENTS AND, EAST MONEY INFORMATION, Longi Green, ZHONGJI INNOLIGHT, SERES.


CSI 100 Index Earning Revision (Dec): PING AN INSURANCE, CITIC SECURITIES, SHANDONG GOLD MINING

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Medcaptain Medical Technology / Equity Capital Markets

<ul>
<li>Medcaptain has a certain level of innovation ability, which has solidified the Company’s market position, as evidenced by its leading rankings in China’s infusion workstation and enteral feeding pump market.</li>
<li>However, multiple niche markets where Medcaptain operates are all in a state of high competition/high concentration. Certain of Medcaptain’s products are facing the risk of VBP, leading to performance uncertainties. </li>
<li>Post-Money valuation in 2023 was RMB8.245 billion. Based on the current performance, we think valuation of Medcaptain should be lower than Mindray and Zylox, but would be higher than Microport.</li>
</ul>


Medcaptain has a certain level of innovation ability, which has solidified the Company’s market position, as evidenced by its leading rankings in China’s infusion workstation and enteral feeding pump market.
However, multiple niche markets where Medcaptain operates are all in a state of high competition/high concentration. Certain of Medcaptain’s products are facing the risk of VBP, leading to performance uncertainties. 
Post-Money valuation in 2023 was RMB8.245 billion. Based on the current performance, we think valuation of Medcaptain should be lower than Mindray and Zylox, but would be higher than Microport.


Pre-IPO Medcaptain Medical Technology - The Strength and the Concerns

China

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. manufactures and distributes medical equipment. The Company produces life information supporting, in vitro diagnostic, and medical imaging equipment equipment. Shenzhen Mindray Bio-Medical Electronics also produces supporting reagents.

Shenzhen Mindray Bio-Medical Electronics (300760 CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shenzhen Mindray Bio-Medical Electronics (300760 CH)

China A50 ETFs Rebalance Preview: 5 Changes in June as the AI-Driven Churn Continues

There could be 5 changes in June as the AI theme rolls on and beneficiaries replace old economy stocks. The recent pullback after the earlier...

Brian Freitas

Northbound Flows (4Q2025): CATL, CATL, Moutai, Moutai, Luxshare Precision, Luxshare Precision

We analyzed Northbound connect data for 4Q2025 and highlight flows for CATL, CATL, Moutai, Moutai, Luxshare Precision, Luxshare Precision, WEICHAI...

Ke Yan, CFA, FRM

Aequitas 2026 Asia IPO Pipeline - Hong Kong

In this note, we will take a look at the Asia Pacific IPO pipeline for 2026, starting with Hong Kong before covering other regions in subsequent...

Sumeet Singh

CSI 100 Index Earning Revision (Dec): PING AN INSURANCE, CITIC SECURITIES, SHANDONG GOLD MINING

We highlighted EPS revision on PING AN INSURANCE, CITIC SECURITIES, SHANDONG GOLD MINING, POLY DEVELOPMENTS AND, EAST MONEY INFORMATION, Longi...

Ke Yan, CFA, FRM

Pre-IPO Medcaptain Medical Technology - The Strength and the Concerns

Medcaptain's innovative products have solidified its leading market position in China, but high competition and performance uncertainties may...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

China A50 ETFs Rebalance Preview: 5 Changes in June as the AI-Driven Churn Continues

There could be 5 changes in June as the AI theme rolls on and beneficiaries replace old economy stocks. The recent pullback after the earlier...

Brian Freitas

Northbound Flows (4Q2025): CATL, CATL, Moutai, Moutai, Luxshare Precision, Luxshare Precision

We analyzed Northbound connect data for 4Q2025 and highlight flows for CATL, CATL, Moutai, Moutai, Luxshare Precision, Luxshare Precision, WEICHAI...

Ke Yan, CFA, FRM

Aequitas 2026 Asia IPO Pipeline - Hong Kong

In this note, we will take a look at the Asia Pacific IPO pipeline for 2026, starting with Hong Kong before covering other regions in subsequent...

Sumeet Singh

CSI 100 Index Earning Revision (Dec): PING AN INSURANCE, CITIC SECURITIES, SHANDONG GOLD MINING

We highlighted EPS revision on PING AN INSURANCE, CITIC SECURITIES, SHANDONG GOLD MINING, POLY DEVELOPMENTS AND, EAST MONEY INFORMATION, Longi...

Ke Yan, CFA, FRM

Pre-IPO Medcaptain Medical Technology - The Strength and the Concerns

​Medcaptain's innovative products have solidified its leading market position in China, but high competition and performance uncertainties may...

Xinyao (Criss) Wang

Medcaptain's innovative products have solidified its leading market position in China, but high competition and performance uncertainties may...